Suppr超能文献

索他洛尔转复心房颤动患者的 QT 日间分析。

Diurnal QT analysis in patients with sotalol after cardioversion of atrial fibrillation.

机构信息

Division of Cardiology, Department of Clinical Science and Education, Karolinska Institutet, South Hospital, Stockholm, Sweden.

Department of Clinical Sciences, Karolinska Institutet, Danderyd, Sweden.

出版信息

Ann Noninvasive Electrocardiol. 2021 Jul;26(4):e12834. doi: 10.1111/anec.12834. Epub 2021 Feb 25.

Abstract

BACKGROUND

The risk of ventricular arrhythmias in patients on QT prolonging drugs is indicated to be increased early after cardioversion (CV) of atrial fibrillation (AF) to sinus rhythm (SR). Sotalol, used to prevent AF relapse, prolongs cardiac repolarization and corrected QT interval (QTc). A pronounced QTc prolongation is an established marker of pro-arrhythmias. Our objective was to use novel technique to quantify and evaluate the diurnal variation of the QTc interval after elective CV to SR in patients on sotalol or metoprolol.

METHODS

Fifty patients underwent twelve-lead Holter recording for 24 hr after elective CV for persistent AF. All patients had the highest tolerable stable dose of sotalol (n = 27) or metoprolol (n = 23). Measurements of QT and RR intervals were performed on all valid beats.

RESULTS

A clear diurnal variation of both HR and QTc was seen in both groups, more pronounced in patients on sotalol, where a high percentage of heartbeats with QTc >500 ms was observed, especially at night. Six patients (22%) on sotalol but none on metoprolol had >20% of all heart beats within the 24-hour recording with QTc >500 ms.

CONCLUSION

Twenty-four-hour Holter recordings with QT-measurement immediately after CV demonstrated that one in five patients on sotalol had >20% of all heart beats with prolonged QTc >500 ms, especially during night-time. The QTc diurnal variation was retained in patients on β-blockade or a potent class III anti-arrhythmic drug with β-blocking properties.

摘要

背景

在心房颤动(AF)转复为窦性心律(SR)后早期,使用延长 QT 间期的药物增加了发生室性心律失常的风险。索他洛尔用于预防 AF 复发,可延长心脏复极和校正 QT 间期(QTc)。明显的 QTc 延长是致心律失常的既定标志物。我们的目的是使用新的技术来量化和评估索他洛尔或美托洛尔治疗患者择期 CV 后 QTc 间期的昼夜变化。

方法

五十名持续性 AF 患者行择期 CV 后进行 24 小时 12 导联 Holter 记录。所有患者均服用最大耐受稳定剂量的索他洛尔(n = 27)或美托洛尔(n = 23)。对所有有效心搏进行 QT 和 RR 间期测量。

结果

两组患者均可见明显的 HR 和 QTc 昼夜变化,索他洛尔组更明显,其中观察到 QTc > 500 ms 的高比例心搏,尤其是夜间。六名(22%)服用索他洛尔的患者但无一名服用美托洛尔的患者在 24 小时记录中超过 20%的心搏 QTc > 500 ms。

结论

CV 后立即进行 24 小时 Holter 记录和 QT 测量显示,五分之一服用索他洛尔的患者 > 20%的心搏 QTc > 500 ms,尤其是夜间。β受体阻滞剂或具有β受体阻滞特性的强效 III 类抗心律失常药物治疗的患者保留 QTc 昼夜变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/342c/8293609/5d71e76461d1/ANEC-26-e12834-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验